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Aim: To evaluate the efﬁcacy/safety of canagliﬂozin twice daily (BID) compared with placebo in patients
with type 2 diabetes mellitus (T2DM) on metformin.
Methods: In this 18-week, randomized, double-blind, placebo-controlled study, patients (N ¼ 279) at 60
centers in 7 countries received canagliﬂozin 50 or 150 mg or placebo BID. The pre-speciﬁed primary
endpoint was change from baseline in HbA1c at Week 18. Pre-speciﬁed secondary endpoints included
proportion of patients reaching HbA1c <7.0%, change in fasting plasma glucose (FPG), and percent change
in body weight; changes in systolic blood pressure (BP) and fasting plasma lipids were also evaluated.
Adverse events (AEs) were recorded throughout the study.
Results: From a mean baseline HbA1c of 7.6% (60 mmol/mol), canagliﬂozin 50 and 150 mg BID signiﬁcantly
reduced HbA1c compared with placebo at Week 18 (0.45%, 0.61%, 0.01% [5, 7, 0.1 mmol/mol],
respectively; P < 0.001). More patients achieved HbA1c <7.0% with canagliﬂozin than placebo (P < 0.05).
Relative to placebo, both canagliﬂozin doses signiﬁcantly lowered FPG and body weight (P < 0.001), and
reduced systolic BP. Overall AE incidence was 35.5%, 40.9%, and 36.6% with canagliﬂozin 50 and 150 mg BID
and placebo, respectively. Canagliﬂozinwas associated with increased incidences of urinary tract infections,
female genital mycotic infections, and osmotic diuresis-related AEs; these led to few discontinuations. The
incidence of documented hypoglycemia was low across groups.
Conclusions: Canagliﬂozin 50 and 150 mg BID provided signiﬁcant glycemic efﬁcacy and body weight
reduction, and were generally well tolerated in patients with T2DM on background metformin.
ClinicalTrials.gov Identiﬁer: NCT01340664
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease that often
requires combination therapy with antihyperglycemic agentsBY-NC-ND license (http://
Published by Elsevier Inc. All right(AHAs) as the disease progresses [1e3]. Metformin is the standard
ﬁrst-line pharmacologic therapy for patients who do not achieve
and maintain adequate glycemic control with diet and exercise
alone [2]. Metformin is a biguanide that reduces hepatic glu-
cose production and improves peripheral insulin sensitivity;
immediate-release (IR) formulations of metformin are typically
administered twice daily (BID) [4]. For patients on metformin
monotherapy who require better glycemic control, several classes
of AHAs may be added as dual therapy; however, some of these
agents are associated with adverse effects such as weight gain ors reserved.
Figure 1. Study ﬂow diagram. PBO, placebo; CANA, canagliﬂozin; BID, twice daily; AE, adverse event; eGFR, estimated glomerular ﬁltration rate; mITT, modiﬁed intent-to-treat.
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AHAs has been shown to be impacted by patients’ baseline HbA1c
values, with greater HbA1c lowering observed in patients with
higher baseline HbA1c [5].
Canagliﬂozin is a sodium glucose co-transporter 2 (SGLT2) in-
hibitor developed for the treatment of adult patients with T2DM
[6e15]. Canagliﬂozin reduces plasma glucose in individuals with
hyperglycemia by inhibiting renal glucose reabsorption and
increasing urinary glucose excretion, and is associated with a mild
osmotic diuresis. In Phase 3 studies in patients with T2DM, once-
daily (QD) doses of canagliﬂozin 100 and 300 mg provided glyce-
mic improvements and reductions in body weight and systolic
blood pressure (BP), and were generally well tolerated as mono-
therapy and in combination with a variety of other AHAs [7e13,15].
This 18-week, Phase 2 study evaluated the efﬁcacy and safety of
canagliﬂozin BID dosing, comparedwith placebo, as add-on therapy
in patients with T2DM inadequately controlled with metformin
monotherapy, to support the development of a ﬁxed-dose combi-
nation of canagliﬂozin and metformin IR.Patients, materials, and methods
Patients and study design
This was a randomized, double-blind, placebo-controlled,
Phase 2 study conducted at 60 centers in 7 countries (ClinicalTrials.
gov Identiﬁer: NCT01340664). The study consisted of a 2-week,
single-blind, placebo run-in period; an 18-week, double-blind,
treatment period; and a 30-day, post-treatment follow-up period.
EligiblepatientsweremenandwomenwithT2DMaged18e80years
who had inadequate glycemic control (HbA1c 7.0% [53 mmol/mol]
and 10.5% [91 mmol/mol]) on metformin monotherapy at
protocol-speciﬁed doses (2000mg/day, or1500mg/day if unable
to tolerate a higher dose) for 8 weeks prior to screening. Patients
also had fasting plasma glucose (FPG)<15 mmol/L at Week e2, and
fasting ﬁngerstick glucose 6.1 and <15 mmol/L on Day 1.
Patients were excluded from the study if they had repeated
FPG and/or fasting self-monitored blood glucose 15.0 mmol/L
during the pretreatment phase; history of type 1 diabetes or
diabetic ketoacidosis; history of cardiovascular disease (including
myocardial infarction, unstable angina, revascularization procedure,or cerebrovascular accident) within 3 months before screening; un-
controlled hypertension; treatment with a peroxisome proliferator-
activated receptor g agonist, insulin, another SGLT2 inhibitor, or
any other AHA (except metformin monotherapy) within 12 weeks
before screening; or estimated glomerular ﬁltration rate
(eGFR) <55 mL/min/1.73 m2 (or <60 mL/min/1.73 m2 if based upon
restriction in localmetformin label) or serum creatinine124 mmol/L
(men) or 115 mmol/L (women).
Eligible patients ﬁrst entered the single-blind, placebo run-in
period, during which they received placebo capsules matching
the double-blind study drug. Patients were instructed to take pla-
cebo BID, with 1 capsule given with the morning meal and 1 given
with the eveningmeal, alongwithmetformin at eachmeal. Patients
took the last dose of single-blind placebo the day before the base-
line (Day 1) visit. Patients whomet all enrollment criteriawere then
randomized to receive canagliﬂozin 50 or 150 mg or placebo BID in
a 1:1:1 ratio. Randomization was balanced using permuted blocks
and was stratiﬁed according towhether the patient’s HbA1c value at
Week e2 was <8.0% or 8.0%. During the double-blind period,
patients took their ﬁrst dose of canagliﬂozin 50 or 150 mg or pla-
cebo on Day 1 at the study center. The last dose of the double-blind
period was taken with the evening meal on the day prior to the
Week 18 visit. After randomization, HbA1c and FPG values were
masked to study centers; FPG values were unmasked if they met
speciﬁc glycemic withdrawal criteria (>15.0 mmol/L after Day 1
through Week 6, >13.3 mmol/L after Week 6 throughWeek 12, and
>11.1 mmol/L after Week 12 through Week 18).
This study was conducted in accordance with ethical principles
that comply with the Declaration of Helsinki, and are consistent
with Good Clinical Practices and applicable regulatory re-
quirements. The study protocol and amendments were approved by
institutional review boards at participating institutions. All parti-
cipants provided written informed consent prior to participation.Endpoints and assessments
The pre-speciﬁed primary endpoint was change from baseline in
HbA1c at Week 18. Pre-speciﬁed secondary endpoints at Week 18
included change in FPG, percent change in body weight, and the
proportion of patients achieving HbA1c <7.0% (53 mmol/mol). It
was noted that w20% of patients who were eligible for the trial
R. Qiu et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 54e6056(based on HbA1c 7.0% at Week e2) had a baseline HbA1c <7.0%;
therefore, a pre-speciﬁed sensitivity analysis was performed to
assess change in HbA1c in patients with baseline HbA1c 7.0%
(53 mmol/mol). Changes in systolic and diastolic BP and percent
changes in fasting plasma lipids (including triglycerides, high-
density lipoprotein cholesterol [HDL-C], low-density lipoprotein
cholesterol [LDL-C], LDL-C/HDL-C ratio, and noneHDL-C) were also
assessed.
Safety was evaluated based on adverse event (AE) reports, safety
laboratory tests, vital sign measurements, 12-lead electrocardio-
grams, and physical examinations. AEs pre-speciﬁed for additional
data collection included urinary tract infections (UTIs) and genital
mycotic infections. Assessment of documented hypoglycemia epi-
sodes included biochemically documented episodes (concurrent
ﬁngerstick or plasma glucose 3.9 mmol/L with or without symp-
toms) and severe episodes (i.e., those requiring the assistance of
another individual or resulting in seizure or loss of consciousness).Statistical analyses
Sample size determination was based on the primary objective
of demonstrating the superiority of canagliﬂozin 150 mg BID vs
placebo in lowering HbA1c at Week 18. Using a 2-sample, 2-sided
t-test with a type I error rate of 0.05, and assuming a group dif-
ference of 0.5% and a common standard deviation (SD) of 1.0%, 85
patients per group were estimated to be required to achieve 90%
power. Sample size was expanded to 90 patients per group to
account for potential patients with missing HbA1c values at study
endpoint.
Efﬁcacy analyses were performed using the modiﬁed intent-to-
treat (mITT) population, consisting of all randomized patients who
received 1 dose of study drug. The last observation carried for-
ward (LOCF) approach was used to impute missing efﬁcacy data.
Safety analyses were performed on the same population analyzed
according to the predominant treatment received; in this study, the
safety analysis set was identical to the mITT analysis set.Table 1






Male 46 (49.5) 40 (43.0
Female 47 (50.5) 53 (57.0
Age, y 57.0 (9.3) 58.6 (8.9
Race, n (%)b
White 73 (78.5) 75 (80.6
Black or African American 4 (4.3) 5 (5.4)
Asian 9 (9.7) 3 (3.2)
Otherc 7 (7.5) 10 (10.8
HbA1c, % (mmol/mol) 7.7  0.9 (61  9.8) 7.6  0.9
Category, n (%)
<7.0% 20 (21.5) 21 (22.6
7.0% 73 (78.5) 72 (77.4
FPG, mmol/L 9.0  1.9 9.0  2.0
Body weight, kg 90.5  18.1 91.2  2
BMI, kg/m2 32.3  5.7 33.0  7
Duration of diabetes, y 7.0  6.4 6.7  4.9
eGFR, mL/min/1.73 m2 84.8  16.5 86.9  1
Metformin treatment at baseline
Category, n (%)
Extended release 24 (26) 20 (22)
Immediate release 69 (74) 73 (78)
Mean daily dose, mg/d 2131  343.1 2137 
PBO, placebo; CANA, canagliﬂozin; BID, twice daily; FPG, fasting plasma glucose; BMI, bo
aData are mean  SD unless otherwise indicated.
bPercentages may not total 100.0% due to rounding.
cIncludes American Indian or Alaska Native, Native Hawaiian or other Paciﬁc IslanderPrimary and continuous secondary efﬁcacy endpoints were
assessed using an analysis of covariance (ANCOVA) model with
treatment and stratiﬁcation factors (i.e., whether or not HbA1c at
screening was 8.0%) as ﬁxed effects and the corresponding
baseline value as a covariate. Least squares (LS) mean differences
between treatment groups and the associated 2-sided 95% conﬁ-
dence intervals (CIs) were estimated based on this model. A mixed
model for repeated measures (MMRM), based on restricted
maximum likelihood, was also pre-speciﬁed as a sensitivity
analysis for the primary efﬁcacy analysis, in order to assess the
data longitudinally. The categorical secondary efﬁcacy endpoint
(i.e., proportion of patients reaching HbA1c <7.0% [53 mmol/mol])
was analyzed using a logistic regression model including terms for
treatment and stratiﬁcation factor, and adjusting for baseline
HbA1c as a covariate. A pre-speciﬁed, hierarchical testing sequence
was implemented to strongly control overall type I error due to
multiplicity. All statistical tests were interpreted at a 2-sided sig-
niﬁcance level of 0.05, and P values are reported for pre-speciﬁed
comparisons only.Results
Patient disposition and baseline characteristics
A total of 279 patients were randomized, all of whom received
1 dose of study drug and were included in the mITT analysis
set; of these, 251 (90%) completed 18 weeks of treatment
(Figure 1). The rate of study discontinuation before Week 18 was
8.6%, 14.0%, and 7.5% with canagliﬂozin 50 and 150 mg BID and
placebo, respectively. The 3 most common reasons for discon-
tinuation were AEs (2.9%), withdrawal of consent (2.2%), and
other (1.8%). Baseline demographic and disease characteristics
were generally similar across groups (Table 1). Notably, 22.2% of
patients had HbA1c <7.0% (53 mmol/mol) at baseline, despite the
inclusion criteria of HbA1c 7.0% (53 mmol/mol) and 10.5%




) 44 (47.3) 130 (46.6)
) 49 (52.7) 149 (53.4)
) 56.7 (10.3) 57.4 (9.5)
) 83 (89.2) 231 (82.8)
1 (1.1) 10 (3.6)
6 (6.5) 18 (6.5)
) 3 (3.2) 20 (7.2)
(60  9.8) 7.6  0.9 (60  9.8) 7.6  0.9 (60  9.8)
) 21 (22.6) 62 (22.2)
) 72 (77.4) 217 (77.8)
9.1  1.9 9.0  1.9
3.9 90.2  19.1 90.6  20.4
.0 32.3  6.8 32.5  6.5
7.3  6.0 7.0  5.8
8.0 85.9  15.3 85.9  16.6
15 (16) 59 (21)
78 (84) 220 (79)
304.1 2128  341.6 2132  328.9
dy mass index; eGFR, estimated glomerular ﬁltration rate; SD, standard deviation.




Figure 2. Changes in efﬁcacy parameters (LOCF). (A) Change in HbA1c over time, (B) mean HbA1c over time, (C) change in HbA1c at Week 18 in patients with baseline HbA1c 7.0%,
(D) change in FPG over time, and (E) percent change in body weight over time. LOCF, last observation carried forward; FPG, fasting plasma glucose; PBO, placebo; CANA, cana-
gliﬂozin; BID, twice daily; LS, least squares; SE, standard error; CI, conﬁdence interval. (To convert values for HbA1c in % into mmol/mol, subtract 2.15 and multiply by 10.929, or use
the conversion calculator at www.HbA1c.nu/eng/)
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Glycemic parameters
From a mean baseline HbA1c of 7.6% (60 mmol/mol), canagli-
ﬂozin 50 and 150 mg BID signiﬁcantly reduced HbA1c from baseline
compared with placebo at Week 18, with differences in LS mean
changes of 0.44% (5 mmol/mol) and 0.60% (7 mmol/mol),
respectively (P< 0.001 for both; Figure 2A and B). The pre-speciﬁed
MMRM analysis showed similar changes in HbA1c. Signiﬁcantly
higher proportions of patients achievedHbA1c<7.0% (53mmol/mol)
at Week 18 with canagliﬂozin 50 and 150 mg BID compared with
placebo (47.8%, 57.1%, and 31.5%, respectively; P< 0.05 and P< 0.001
vs placebo, respectively). In the pre-speciﬁed sensitivity analysis in
patientswith baselineHbA1c7.0%, canagliﬂozin 50 and 150mgBID
reduced HbA1c compared with placebo (differences in LS mean
changes of 0.5% [6 mmol/mol] and 0.7% [8 mmol/mol];
Figure 2C).
Both canagliﬂozin doses signiﬁcantly reduced FPG compared
with placebo (differences in LS mean changes of 1.3 mmol/L
for both; P < 0.001; Figure 2D). The median reductions in FPGwere 0.7 and 1.2 mmol/L with canagliﬂozin 50 and 150 mg
BID, while a median increase in FPG was seen with placebo
(0.3 mmol/L).
Body weight, BP, and lipids
Relative to placebo, canagliﬂozin 50 and 150 mg BID signiﬁ-
cantly reduced body weight at Week 18 (differences in LS mean
changes of 2.2% and 2.6%, respectively; P < 0.001; Figure 2E).
Changes from baseline in BP and fasting plasma lipids at Week 18
are presented in Table 2. Canagliﬂozin 50 and 150 mg BID lowered
systolic BP compared with placebo at Week 18 (differences in LS
mean changes of 5.4 and 5.7 mmHg, respectively). Diastolic BP
was also reduced with both canagliﬂozin doses vs placebo, with
minimal changes in pulse rate observed across groups (mean
changes of 0.9, 1.4, and 0.0 beats per minute with canagliﬂozin 50
and 150 mg BID and placebo, respectively). Canagliﬂozin 150 mg
BID was associated with an LS mean percent increase in tri-
glycerides compared with canagliﬂozin 50 mg BID and placebo. A
median percent decrease in triglycerides was seen with canagli-
ﬂozin 150 mg BID, suggesting that the change in LS means may be
Table 2
Summary of changes in BP and fasting plasma lipids at Week 18 (LOCF)a
Parameter PBO (n ¼ 93) CANA 50 mg BID (n ¼ 93) CANA 150 mg BID (n ¼ 93)
Systolic BP, n 92 90 91
Mean  SD baseline, mmHg 128.6  11.0 131.1  12.4 128.2  12.0
LS mean  SE change 3.3  1.1 2.1  1.1 2.4  1.1
Difference vs PBO (95% CI) 5.4 (8.4, 2.3) 5.7 (8.7, 2.6)
Diastolic BP, n 92 90 91
Mean  SD baseline, mmHg 77.8  7.2 78.1  7.4 78.5  7.7
LS mean change  SE 1.2  0.7 1.2  0.7 1.8  0.7
Difference vs PBO (95% CI) 2.4 (4.3, 0.4) 3.1 (5.0, 1.1)
Triglycerides, n 88 90 88
Mean  SD baseline, mmol/L 2.0  1.3 1.9  0.8 2.2  1.7
LS mean  SE change 0.06  0.09 0.02  0.09 0.00  0.09
Median percent change (95% CI) 1.4 (10.7, 7.7) 4.2 (3.7, 10.5) 1.4 (17.2, 9.7)
LS mean  SE percent change 6.7  4.8 5.5  4.7 13.7  4.8
Difference vs PBO (95% CI) 1.2 (14.3, 12.0) 7.0 (6.2, 20.3)
LDL-C, n 87 90 88
Mean  SD baseline, mmol/L 2.6  1.1 2.8  1.0 2.7  0.9
LS mean  SE change 0.13  0.07 0.18  0.07 0.10  0.07
Median percent change (95% CI) 4.3 (3.1, 9.4) 3.6 (0.7, 8.7) 5.1 (0.7, 10.3)
LS mean  SE percent change 8.6  3.0 10.4  2.9 7.9  3.0
Difference vs PBO (95% CI) 1.8 (6.5, 10.1) 0.7 (9.0, 7.6)
HDL-C, n 87 90 88
Mean  SD baseline, mmol/L 1.2  0.3 1.2  0.3 1.3  0.3
LS mean  SE change 0.03  0.02 0.04  0.02 0.10  0.02
Median percent change (95% CI) 2.3 (1.5, 6.1) 2.7 (0.0, 6.2) 6.8 (2.9, 10.9)
LS mean  SE percent change 2.6  1.5 3.8  1.5 8.9  1.5
Difference vs PBO (95% CI) 1.2 (3.0, 5.5) 6.4 (2.1, 10.6)
LDL-C/HDL-C, n 87 90 88
Mean  SD baseline, mol/mol 2.2  0.9 2.4  0.9 2.2  0.8
LS mean  SE change 0.06  0.07 0.12  0.07 0.06  0.07
Median percent change (95% CI) 2.0 (0.7, 6.5) 1.4 (5.4, 7.7) 3.4 (7.6, 1.3)
LS mean  SE percent change 6.6  3.1 8.3  3.1 0.9  3.1
Difference vs PBO (95% CI) 1.6 (7.0, 10.3) 5.7 (14.3, 2.9)
NoneHDL-C, n 87 89 88
Mean  SD baseline, mmol/L 3.5  1.2 3.7  1.1 3.7  1.1
LS mean  SE change 0.12  0.09 0.21  0.09 0.11  0.09
Median percent change (95% CI) 2.6 (3.7, 8.1) 4.1 (0.9, 8.3) 3.2 (0.3, 6.5)
LS mean  SE percent change 5.9  2.7 8.4  2.7 5.9  2.7
Difference vs PBO (95% CI) 2.6 (5.0, 10.1) 0.1 (7.5, 7.6)
BP, blood pressure; LOCF, last observation carried forward; PBO, placebo; CANA, canagliﬂozin; BID, twice daily; SD, standard deviation; LS, least squares; SE, standard error; CI,
conﬁdence interval; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
aStatistical comparisons vs PBO not performed (not pre-speciﬁed).
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a modest median percent increase in triglycerides relative to the
placebo. A larger increase in HDL-C was also seenwith canagliﬂozin
150 mg BID compared with canagliﬂozin 50 mg BID and placebo.
Minimal changes were observed with canagliﬂozin vs placebo in
LDL-C and noneHDL-C. Canagliﬂozin 150 mg BID was associated
with a decrease in LDL-C/HDL-C ratio compared with canagliﬂozin
50 mg BID and placebo.
Safety
The overall incidence of AEs was 35.5%, 40.9%, and 36.6% with
canagliﬂozin 50 and 150 mg BID and placebo, respectively, over 18
weeks (Table 3). The incidence of serious AEs was low across groups
(0%, 3.2%, and 1.1% with canagliﬂozin 50 and 150 mg BID and pla-
cebo, respectively). The incidence of AEs leading to discontinuation
was 1.1% (1 patient), 7.5% (7 patients), and 0% with canagliﬂozin 50
and 150 mg BID and placebo, respectively. In the canagliﬂozin
150 mg BID group, 2 patients discontinued the study due to AEs of
vulvovaginal pruritus; no other individual speciﬁc AE term led to
discontinuation in more than 1 patient.
Canagliﬂozin 50 and 150 mg BID were associated with a higher
incidence of UTIs (4.3% for both) compared with placebo (2.2%).
Most UTIs in canagliﬂozin-treated patients weremild and only 1 led
to study discontinuation; 1 (1.1%) patient in the canagliﬂozin
150 mg BID group who had an indwelling urinary catheter reported
an upper UTI (pyelonephritis) that was a serious AE. Canagliﬂozin50mg BIDwas associatedwith a higher incidence of genital mycotic
infections in females than canagliﬂozin 150 mg BID and placebo
(11.3%, 2.0%, and 4.3%, respectively); most events with canagliﬂozin
weremild or moderate in intensity and none led to discontinuation.
Two males reported genital mycotic infections: 1 (2.5%) in the
canagliﬂozin 50 mg BID group and 1 (2.2%) in the placebo group.
The incidence of AEs related to osmotic diuresis (e.g., pollakiuria
[increased urine frequency]) was 7.5% with canagliﬂozin 150 mg
BID, with none reported in the other groups; all events were mild
and none led to discontinuation. No AEs related to volume deple-
tion (e.g., postural dizziness, orthostatic hypotension) were
reported.
The incidence of documented hypoglycemiawas low and similar
across groups (4.3%, 3.2%, and 3.2% with canagliﬂozin 50 and
150 mg BID and placebo, respectively). No severe hypoglycemia
events were reported.
Generally, only small differences were observed with canagli-
ﬂozin relative to placebo in mean percent changes from baseline in
laboratory parameters over 18 weeks (Supplementary Table 1).
Reductions in alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were observed with canagliﬂozin 150 mg
BID, whereas increases were seenwith canagliﬂozin 50 mg BID and
placebo. Mean percent increases in serum bilirubin and blood urea
nitrogen were observed across groups, with relatively higher in-
creases in canagliﬂozin-treated patients compared with those
receiving placebo. Small decreases in eGFR were observed across
Table 3




CANA 50 mg BID
(n ¼ 93)
CANA 150 mg BID
(n ¼ 93)
Any AE 34 (36.6) 33 (35.5) 38 (40.9)
AEs leading to discontinuation 0 1 (1.1)a 7 (7.5)b
AEs related to study drugc 2 (2.2) 11 (11.8) 15 (16.1)
Serious AEs 1 (1.1) 0 3 (3.2)
Deaths 0 0 1 (1.1)
Selected AEs
UTI 2 (2.2) 4 (4.3) 4 (4.3)
Genital mycotic infection
Maled,e 1 (2.2) 1 (2.5) 0
Femalef,g 2 (4.3) 6 (11.3) 1 (2.0)
Osmotic diuresiserelated AEsh 0 0 7 (7.5)
Volume depletion AEs 0 0 0
AE, adverse event; PBO, placebo; CANA, canagliﬂozin; BID, twice daily; UTI, urinary tract infection.
aSpeciﬁc term of headache.
bSpeciﬁc terms included colon cancer (n ¼ 1), dermatitis allergic (n ¼ 1), glomerular ﬁltration rate decreased (n ¼ 1), nephrolithiasis (n ¼ 1), palpitations (n ¼ 1),
pyelonephritis (n¼ 1), and vulvovaginal pruritus (n¼ 2). One patient experienced 2 AEs (pyelonephritis and nephrolithiasis) that were reported to lead to discontinuation.
cPossibly, probably, or very likely related to study drug, as assessed by investigators.
dPBO, n ¼ 46; CANA 50 mg BID, n ¼ 40; CANA 150 mg BID, n ¼ 44.
eIncluding balanitis candida and genital infection fungal.
fPBO, n ¼ 47; CANA 50 mg BID, n ¼ 53; CANA 150 mg BID, n ¼ 49.
gIncluding vaginal infection, vulvovaginal candidiasis, vulvovaginal mycotic infection, and vulvovaginitis.
hIncluding dry mouth, micturition urgency, pollakiuria, and thirst.
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Decreases in serum urate were observed with both canagliﬂozin
doses, whereas minimal changewas seenwith placebo. Increases in
hemoglobin were observed with both canagliﬂozin doses vs pla-
cebo. Median percent changes generally showed similar trends
(Supplementary Table 1); differences between mean and median
changes in some parameters (i.e., ALT, AST, and bilirubin) may be
related to outliers.
Discussion
This Phase 2 study evaluated the efﬁcacy and safety of canagli-
ﬂozin BID dosing in patients with T2DM inadequately controlled on
maximally effective doses of metformin monotherapy, in support of
the development of a ﬁxed-dose combination of canagliﬂozin and
metformin IR. Canagliﬂozin doses of 50 and 150 mg BID were
selected to provide the same total daily doses (i.e., 100 and 300 mg
QD) as those approved for the treatment of patients with T2DM [6].
Canagliﬂozin 50 and 150 mg BID provided signiﬁcant improve-
ments in glycemic control and reductions in body weight compared
with placebo. In the overall patient population with a lower than
expected HbA1c at baseline (mean HbA1c of 7.6% [60 mmol/mol])
resulting from the high proportion of patients with HbA1c <7.0%,
both canagliﬂozin doses signiﬁcantly reduced HbA1c, and a higher
proportion of canagliﬂozin-treated patients achieved HbA1c <7.0%
(53 mmol/mol) compared with placebo at Week 18. Reductions in
HbA1c from baseline were also seenwith canagliﬂozin vs placebo in
a pre-speciﬁed sensitivity analysis in patients with baseline HbA1c
values 7.0% (53 mmol/mol). Both canagliﬂozin doses were asso-
ciated with reductions in FPG, body weight, and systolic and dia-
stolic BP. Canagliﬂozin 150 mg BID was associated with a mean
increase in triglycerides; however, a median percent decrease in
triglycerides was seen with canagliﬂozin 150 mg BID, suggesting
that the change in LS means may be inﬂuenced by outliers. Cana-
gliﬂozin 150 mg BID was also associated with an increase in HDL-C,
compared with canagliﬂozin 50 mg BID and placebo. No notable
differences were observed across treatment groups in LDL-C,
whereas dose-related increases in LDL-C have been observed in
other Phase 3 studies of canagliﬂozin [7,9e13,15]. Differences inlipid outcomes relative to other canagliﬂozin studies may be
derived from the small population in the present study.
Overall, efﬁcacy ﬁndings with canagliﬂozin 50 and 150 mg BID in
the present study were generally consistent with those observed in
Phase 3 studies of canagliﬂozin 100 and 300 mg QD [7e13,15], with
the canagliﬂozin 150 mg BID dose providing an incremental beneﬁt
in HbA1c and body weight reduction relative to the canagliﬂozin
50 mg BID dose. The lack of a dose-response in FPG changes may
reﬂect an impact of outlying data, as the median reduction in FPG
was greater with canagliﬂozin 150 mg BID than with canagliﬂozin
50 mg BID (1.2 vs 0.7 mmol/L). The absence of substantive dif-
ferences between BID and QD dosing of canagliﬂozin, at the same
total daily doses, was expected based on previous Phase 1 studies
that included both BID and QD dosing [16,17].
Of note, the HbA1c reduction reported for the overall population
in the present study was lower than that reported in prior Phase 3
studies [7e13,15]. In a meta-analysis of the relationship between
baseline glycemia and HbA1c reduction in published studies of oral
AHAs, baseline HbA1c was found to impact HbA1c reductions
following AHA treatment, with a greater apparent treatment effect
observed with higher baseline HbA1c [5]. Thus, the lesser HbA1c
reduction observed in the present 18-week study relative to prior
26-week Phase 3 studies is likely related, in part, to the lower
baseline HbA1c in the overall study population. Consistent with this,
numerically greater HbA1c reductions were observed with both
canagliﬂozin doses vs placebo when assessed in a subset of patients
with baseline HbA1c 7.0% (53 mmol/mol). The difference in gly-
cemic efﬁcacy may also be related to the shorter duration of this
study (18 weeks) compared with previous Phase 3 studies (26e52
weeks). Notably, in the overall study population, signiﬁcantly
higher proportions of canagliﬂozin-treated patients achieved HbA1c
<7.0% (53 mmol/mol) compared with patients treated with pla-
cebo, demonstrating meaningful glycemic efﬁcacy with canagli-
ﬂozin treatment in this population.
Canagliﬂozin 50 and 150 mg BID were generally well tolerated,
with 1 or both doses associated with increased incidences of UTIs,
female genital mycotic infections, and AEs related to osmotic
diuresis. These AEs were generallymild tomoderate in severity, and
infrequently led to study discontinuation. Canagliﬂozin treatment
R. Qiu et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 54e6060was not associated with an increased incidence of hypoglycemia
compared with placebo. The safety proﬁle observed for canagli-
ﬂozin BID dosing in the current study is generally similar to that
seen with prior Phase 3 canagliﬂozin studies [7e13,15].
Despite several potential limitations of the current study,
including the relatively small number of patients enrolled in the
study, a generally lower baseline HbA1c in this patient population
compared with those in Phase 3 studies, and a low representation
of some races/ethnicities in the patient population (as a function of
study centers), ﬁndings were generally consistent with Phase 3
studies of canagliﬂozin. Longer-term studies of canagliﬂozin 50 and
150 mg BID in larger and broader patient populations may be
helpful for further elucidation of the efﬁcacy and safety of cana-
gliﬂozin BID dosing regimens. Furthermore, it would be beneﬁcial
to include canagliﬂozin 100 and 300 mg QD arms in future studies
to allow for direct comparisons of BID and QD dosing.
In conclusion, canagliﬂozin BID dosing, at total daily doses of 100
and 300 mg, provided signiﬁcant glycemic efﬁcacy. Reductions in
HbA1c were modest, consistent with the lower baseline HbA1c in
the present study compared with previous Phase 3 studies of can-
agliﬂozin. Reductions in body weight and systolic BP were also
observed, and canagliﬂozin BIDwas generally well tolerated as add-
on to metformin monotherapy. Overall, ﬁndings from this study
indicate a favorable efﬁcacy and safety/tolerability proﬁle of cana-
gliﬂozin in combination with metformin.
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